Last reviewed · How we verify
COP
COP is a corticosteroid that reduces inflammation and swelling in the body.
COP is a corticosteroid that reduces inflammation and swelling in the body. Used for Chronic obstructive pulmonary disease (COPD), Asthma.
At a glance
| Generic name | COP |
|---|---|
| Also known as | Cyclophosphamide, Oncovin (vincristine), and Prednisone |
| Sponsor | Acrotech Biopharma Inc. |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Corticosteroids like COP work by binding to glucocorticoid receptors in the body, which then reduces the production of inflammatory chemicals. This leads to a decrease in inflammation and swelling, making it easier to manage conditions like COPD.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma
Common side effects
- Oral thrush
- Weight gain
- Increased risk of infections
- Bone loss
- Glaucoma
- Cataracts
- Hypersensitivity reactions
- Increased blood sugar
- Increased blood pressure
- Nausea
Key clinical trials
- Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL (PHASE2)
- Boosting Regional Integration for COP D Care Through Guided Implementation and Audit of Post Exacerbation Transition Bundle
- Assessment of Trunk Control and Postural Instability in Patients With Various Neurological Disorders (Stroke, Parkinson, Sclerosis Multiplex) Using Objective Tools (TecnoBody ProKin Posturometry, 3D Motion Analysis) (NA)
- Virtual Reality-Based Rehabilitation After Stroke: A Randomized Controlled Trial (NA)
- Reactive Balance Training vs Virtual Reality in Hemiplegic Cerebral Palsy (NA)
- Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients (PHASE3)
- Vaccine- and Infection-derived Correlates of Protection for Cholera. (NA)
- tAN for First Responders (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COP CI brief — competitive landscape report
- COP updates RSS · CI watch RSS
- Acrotech Biopharma Inc. portfolio CI